Michael Barbella, Managing Editor07.01.23
M&A and new products took top billing on ODT's website this past week.
Acquisitions of utmost interest to cybervisitors were Zavation Medical Products' purchase of spinal implant/instrument provider CoreLink, and the Enovis-Novastep deal closing. The latter transaction reportedly will strengthen Enovis' position in the growing bunion market.
New product debuts came from OrthoPediatrics, Anika Therapeutics Inc., and Acuitive Technologies. OrthoPediatrics and Acuitive both announced the first clinical cases with their newest portfolio additions—the new GIRO Growth Modulation System and Citrelock ACL Tendon Fixation Device, respectively, while Anika Therapeutics received an additional FDA 510(k) clearance for its Tactoset Injectable Bone Substitute. The new indication expands the use of Tactoset to be combined with autologous bone marrow aspirate, and increases Tactoset’s commercial reach by combining BMA with Tactoset for treating bone defects such as osteoporotic bone, cysts, and insufficiency fractures.
Acquisitions of utmost interest to cybervisitors were Zavation Medical Products' purchase of spinal implant/instrument provider CoreLink, and the Enovis-Novastep deal closing. The latter transaction reportedly will strengthen Enovis' position in the growing bunion market.
New product debuts came from OrthoPediatrics, Anika Therapeutics Inc., and Acuitive Technologies. OrthoPediatrics and Acuitive both announced the first clinical cases with their newest portfolio additions—the new GIRO Growth Modulation System and Citrelock ACL Tendon Fixation Device, respectively, while Anika Therapeutics received an additional FDA 510(k) clearance for its Tactoset Injectable Bone Substitute. The new indication expands the use of Tactoset to be combined with autologous bone marrow aspirate, and increases Tactoset’s commercial reach by combining BMA with Tactoset for treating bone defects such as osteoporotic bone, cysts, and insufficiency fractures.